INTRODUCTION
The concept that cancers result from aberrant versions of normal developmental processes is very old (von Hansemann, 1897). During the last 10 years, stem cell biology concepts have been reapplied with a new force to the field of cancer biology. Bonnet et al. provide the first evidence for the existence, within human acute myeloid leukemia (AML), of a hierarchical organization reminiscent of a stem cell system [1] . Subsequently, the cancer stem cell (CSC, also known as tumor-initiating or tumor-propagating cell) model has been progressively applied to the study of many other tumor types, especially solid epithelial carcinomas [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
Tumors can be viewed as "caricatures" of normal tissues where different cell types, generated as a result of the processes of multi-lineage differentiation, and are organized into hierarchical structures [17] . The theory that tumor tissues are sustained in their longterm growth by a subset of cancer cells endowed with stem cell properties has significant experimental support. This subset of cancer cells displays two of the hallmark properties of stem cells: capacity for selfrenewal (i.e., the ability to regenerate with intact long-term proliferation and expansion potential) and the ability to differentiate (i.e., the ability to develop to more mature progeny thus generating cellular diversity) [18, 19] .
Using genetic lineage-tracing strategies three different groups independently demonstrated the fate of CSCs in vivo during tumor progression [20] [21] [22] . These studies did not end the CSC debate, as lineage tracing has its own limitations [23] . Driessens et al., in their elegant study, found that benign papillomas are hierarchically organized in vivo in support of the CSC hypothesis [21] . By using a multicolor conditional reporter assay, Schepers et al. discovered that, in accordance with CSC theory, most of the Lgr5 C intestinal cells with CSC properties differentiated into Lgr5
À non-CSCs in vivo, albeit Lgr5
À cells were not being fate mapped in their experiment [22] . Employing fate mapping in a mouse model of glioma, Chen et al. identified a subset of endogenous Nestin C tumor cells that are the source of new tumor cells after the drug temozolomide is administered to transiently arrest tumor growth [20] . The Nestin C cells are main driving force for tumor growth, therapy resistance, and tumor relapse. More recently, an international research team studied a group of patients with myelodysplastic syndromes (MDS, a malignant blood condition), which frequently develops into acute myeloid leukemia, and found that rare Lin À CD34 C CD38 À CD90 C CD45RA À MDS cells function as MDSpropagating cells in patients with low to intermediate risk MDS [24] .
Taken together, these studies define a common methodological frame work for the experimental validation of the CSC model. As a rule, a tumor is usually described as following a CSC model based on the fulfillment of three criteria:
1. Within tumor tissues, only a subset of cancer cells is endowed with tumorigenic capacity when transplanted into immunodeficient mice. These cells are characterized by a distinctive repertoire of surface markers (Table 1) and can be reproducibly purified from other cells that do not have this capacity.
2. Tumors grown from tumorigenic cells contain mixed populations of both tumorigenic and non-tumorigenic cancer cells, thus recreating the phenotypic heterogeneity of the parent tumor.
3. Tumors grown from tumorigenic cells can be serially passaged indicative of self-renewal properties. [25, 26] .
Researchers prone that not all cancers appear to follow the CSC model and that in such cancers, although genetic and/or phenotypic heterogeneities are present, all cells are equally tumorigenic and there is no cellular hierarchy [25, 26] . However, two factors make it difficult to know whether there is a cellular hierarchy in this kind of cancers: CSC plasticity and transience of markers. Further experimental investigation is needed to know whether some cancers, including melanoma, do not follow the CSC model.
Macroautophagy (hereafter referred to as autophagy, see Box 1) is a lysosomal degradative process that acts on cytoplasmic cellular components (such as macromolecules, long-lived proteins, and damaged organelles). Autophagy plays a major role under basal conditions in cytoplasm quality control and cellular homeostasis. In the response to stress, autophagy is induced and acts to promote cell survival by providing nutrients (e.g., amino acids, fatty acids, ATP). Indeed, during period of starvation (such as glucose withdrawal, growth factor or serum deprivation, or hypoxia), the stimulation of the autophagic pathway fuels cells with nutrients via lysosomal recycling to maintain metabolic activity and to respond to the demand for energy.
Autophagy is a multistep cellular process (see Box 2). The master negative regulation of autophagy initiation is mediated by the mammalian target of rapamycin complex 1 (mTORC1), which integrates multiple signaling pathways that are sensitive to the availability of amino acids, ATP, growth factors, and the level of reactive oxygen species (ROS). The modulation of autophagy is now recognized as one of the hallmarks of cancer cells. Depending on the type of cancer and the context, autophagy can serve as a tumor suppressor or it can overcome metabolic stress and the cytotoxicity of chemotherapy to facilitate cancer cell survival. Recent studies have shed light on the role of autophagy in tumor immune response cross-talk with the microenvironment. In this review, we will briefly describe recent advances in the characterization of CSCs, focusing on the role of autophagy in cancer stem cells, and then will discuss the implications of modulating autophagy in therapies designed to target CSCs. [27] . For a long time, tumor heterogeneity was explained by a stochastic clonal model (Figure 1 ), which is based on the notion that all tumor cells are equipotent and can develop into tumors given genetic and/or epigenetic changes. In the CSC model, not all cells in tumors are equal [19] . Tumor tissues are characterized by cellular hierarchy: Only a subset of tumor cells has the ability for long-term self-renewal, and these cells have tumorigenic potential much greater than that other cancer cells. Tumor hierarchical organization consists of stem cells, progenitors, and differentiated cells. Molecular heterogeneity is present not only among different tumors same type (inter-tumor heterogeneity) but also among different regions within the same tumor (intra-tumor heterogeneity) [28] .
Clonal diversity of CSCs
The models of CSC and clonal evolution are likely not mutually exclusive. Instead, cancer cells that match the characteristics predicted by one model or the other likely coexist in a dynamic state. Both models predict that new somatic mutations can generate clonal diversity, which further increases tumor heterogeneity. [19, 203, 204] BOX 1 DIFFERENT FORMS OF AUTOPHAGY AND SELECTIVITY The term of autophagy covers three mechanisms: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Macro-and microautophagy are conserved in all eukaryotic cells, whereas CMA is restricted to mammalian cells. Macroautophagy begins with the formation of a double-membrane-bound vacuole called the autophagosome, which sequesters cytoplasmic material and delivers it to the lysosomal compartment. Microautophagy is the direct engulfment of cytoplasmic material by the lysosomal membrane, and CMA is the lysosomal importation of KFERQ-containing proteins, via their interaction with hsc70 and the lysosomal membrane protein LAMP-2a. Macroautophagy and microautophagy are bulk processes, but, in many cases, they can be highly selective of cellular structures, including peroxisomes (pexophagy), mitochondria (mitophagy), endoplasmic reticulum (reticulophagy), ribosomes (ribophagy), midbody, micro-nuclei and part of the nuclei (nucleophagy), lipid droplets (lipophagy), aggregate-prone proteins (aggrephagy), secretory granules (zymophagy), damaged lysosomes (lysophagy), and microorganisms (xenophagy). The paradigm for selective autophagy is the recognition of the cargo by autophagy receptors that connect the cargo to the autophagy machinery. Autophagy receptors (p62/ SQSTM1, NBR1, NDP52, optineurin) recognize ubiquitylated targets via ubiquitin-associated domains and the protein LC3 via its LC3-interacting region (LIR) motif. In many autophagy receptors, phosphorylation consensus sites are present in the vicinity of the LIR motif. Phosphorylation of these sites has been shown to increase the affinity of the autophagy receptor for LC3. Defects in selective autophagy are accompanied by accumulation of cargo and reduction in turnover of autophagy receptors. These defects disrupt tissue homeostasis and result in diseases. As an example, accumulation of the autophagy receptor p62/SQSTM1 leads to activation of NF-kB and of the transcription factor Nrf2, two events linked with tumorigenesis.
Plasticity of CSCs
The concept of "CSC plasticity" posits that the majority of tumor cells are stem cells with varying degrees of "stemness" governed by microenvironmental cues and other stochastic cell autonomous mechanisms [29] [30] [31] . Although, the underlying molecular mechanism for CSC plasticity is unknown, the concept of plasticity links clonal evolution and CSC models and demands that CSC hierarchy must be seen as bidirectional balance between CSCs and differentiated non-CSCs [32] . CSC plasticity could be a stochastic process or might be orchestrated by microenvironmental signals depending on the type and genetic background of a tumor [23, 33] .
The evidence that some cancer cells can undergo reversible changes in their competence to form tumors offers an alternative explanation for the increased tumorigenic potential of subsets of cancer cells that is independent of the differentiation of CSCs. Some cancer cells can reversibly transition between epithelial and mesenchymal states, and there is evidence that breast cancer cells in the mesenchymal state are more competent than those in the epithelial state to form tumors [34] . However, Xie et al. recently report that the epithelial-mesenchymal transition (EMT) does not alter tumor-initiating capacity of breast cancer cells [35] .
Using the histone demethylase JARID1B as a biomarker, Roesch et al. characterized a distinct subpopulation of slow-cycling melanoma cells that is required for continuous tumor growth [36] . Cells that express JARID1B are more competent to sustain tumor growth than JARID1B-negative cells. Loss of JARID1B results in a reduction in the number of melanoma cell metastases in the lung, leading the authors to conclude that JARID1B might not be necessary for tumor initiation but is probably required for tumor progression and the initial formation of metastases. Quintana et al. also reported that many markers appear to be reversibly expressed by tumorigenic melanoma cells [37] . None of 22 heterogeneously expressed markers, including CD271 and ABCB5, enriched tumorigenic cells. For example melanomas metastasized in mice, irrespective of whether they arose from CD271 À or CD271 C cells. Data suggest that there may not be a hierarchy of tumorigenic and non-tumorigenic cells in melanoma [37] . In skin squamous cell carcinoma, CD34 low cells can generate CD34 hi cells on transplantation. However, CD34 low cells that acquire CD34 expression do not generate secondary tumors with the same efficiency as CD34 hi cells isolated from the primary tumors [38] , suggesting that the reversibility of surface marker expression does not imply that the fate of tumor cells is also fully reversible.
Although lineage tracing studies provide strong evidence in favor of the presence and differentiation of CSCs in vivo in different solid tumors [20] [21] [22] , a recent study showed that Lgr5 À cells can also act as the cell of origin for intestinal adenomas and that these cells do not meet the
BOX 2 ROLE OF ATGS IN AUTOPHAGY
The discovery of autophagy-related (Atg) genes in yeast was a milestone in our understanding of how the autophagosome is formed [202] . Fifteen ATG proteins constitute the core machinery of autophagosome formation. In mammalian cells, these ATGs are hierarchically recruited to form a phagophore, or isolation membrane, that subsequently elongates to form the autophagosome. Recent studies have shown that ATG assembly takes place at the point of contact between the endoplasmic reticulum membrane and the outer membrane of mitochondria. Other membranes, such as those of the endosomes and the Golgi apparatus, and the plasma membrane also contribute to the biogenesis of the autophagosome. Several functional modules involving ATG have been identified during the phases of autophagosome formation from the initiation step to the elongation/closure step. Five functional modules have been defined: the ULK1 complex (ULK1 is the mammalian homolog of yeast Atg1), class III phosphatidylinositol 3-kinase (PIK3C3/Vps34) complex I (which contains PIK3C3 and Beclin 1, the latter is the mammalian homolog of the yeast Atg6). The activation of ULK1 complex is down-regulated by mTORC1, which integrates multiple signaling pathways that are sensitive to the availability of amino acids, ATP, growth factors, and the level of ROS. The two complexes ULK1 and PIK3C3 are involved in the initiation of autophagy. Phosphatidylinositol 3-phosphate (PtdIns3P), which is produced by the enzymatic activity of PIK3C3, recruits WIPI1/2 (homologs of yeast Atg18) at the phagophore, and DFCP1 at the endoplasmic reticulum site of autophagosome formation known as the omegasome. These two PtdIns3P-binding proteins characterize the third functional cassette. One of the functions of WIPI2 is to control the transport of the multispanning membrane ATG9 from the phagophore to a peripheral endosome/Golgi localization. The ATG9 protein makes up the fourth functional cassette. In yeast, the fusion of Atg9-containing vesicles is important in the very early stages of autophagy. In mammalian cells, the trafficking of ATG9 to the phagophore is also an early event that occurs soon after autophagy induction. The last functional module consists of the two ubiquitin-like conjugation systems: ATG12-ATG5 and the LC3-phosphatidylethanolamine (LC3 is the mammalian homolog of yeast Atg8), which are involved in the elongation and closure of the autophagosomal membrane.
criteria of the CSC model [39] . This counter challenging evidence may possibly support the concept of CSC plasticity as it can be taken to suggest that non-CSCs can be dedifferentiated into CSCs since Lgr5 À cells can give rise to Lgr5 C cells in vivo. It is also important to note that nearly all existing reports about reversible transition between CSCs (tumorigenic) and non-CSCs (non-tumorigenic) states come from studies performed using immortalized cell lines [23] . As certain high passage cell lines have been found to show endogenous phenotypic plasticity, it is critical to investigating the extent of such plasticity in spontaneously arising tumors in vivo [32] . In support of in vivo CSC plasticity, Friedmann-Morvinski et al. reported that most differentiated cells in the central nervous system undergo de-differentiation upon defined genetic alterations to generate a neural stem cells or a progenitor state capable of initiating and maintaining tumor progression. These cells can also give rise to the heterogeneous populations observed in malignant gliomas [40] . More in depth in vivo lineage tracing with multicolor labelling of non-CSCs and CSCs may elucidate differentiation hierarchies and confirm CSC plasticity.
Various factors clearly have significant roles in maintaining CSC plasticity as well as solid tumor heterogeneity: 1. genetic instability or DNA mutations, 2. the tumor microenvironment and CSC niche, and 3. microRNAs and other epigenetic factors. Excellent recent reviews have highlighted these various factors [23, 32, 41] . It seems plausible that all these factors are essential for tumor heterogeneity and for CSC plasticity. populations. One example of an interaction between CAFs and tumoral stem cells was reported in ovarian cancer. This interaction results in the activation of the hedgehog (Hh) pathway in aldehyde dehydrogenases positive (ALDH C ) ovarian CSCs and the induction of bone morphogenic proteins (BMPs) 2 and 4, stimulating proliferation [42] . CAFs and TAMs are a source of multiple growth factors and chemokines/cytokines including TGF-b, IL-6, IL-8, and oncostatin M (OSM) that induce the emergence of CSCs associated with EMT in several types of cancers including that of the breast [43] [44] [45] .
A recent study revealed synergistic interactions between endothelial cells and CSCs that promote the malignant properties of glioblastoma CSCs in an IL-8-dependent manner [46] . Endothelial cells not only secrete high levels of IL-8 but also induced CSCs to upregulate the IL-8 cognate receptors CXCR1 and CXCR2, which collectively enhances CSC migration, growth, and stemness properties. Accordingly, in both in vitro and in vivo studies of glioblastoma, Hedgehog and NOTCH ligands (Hh, Jagged-1, respectively) are released from tumor endothelial cells and activate the Hh and NOTCH pathways in tumor cells promoting stem-like characteristics [47, 48] . In similar manner, endothelial cells promote the colorectal CSC phenotype through a soluble form of Jagged-1 [49] . More importantly, these studies revealed the activity of the Hh network in the niche of CSCs in which glioma cells induce, via VEGF pathway, the secretion of Sonic Hh by endothelial cells resulting in the paracrine-mediated activation of Hh pathway in glioma cells. Although the origin of CSCs remains controversial, these data support cell plasticity in which cancer cells may acquire CSC phenotypes through re-programming or de-differentiation process [50, 51] . In further support, it has been reported that glioblastoma stem-like cells are able to differentiate into vascular endothelial like cells or vascular pericytes, raising the possibility that these differentiated cells arise from CSCs and generate a CSC niche [52] [53] [54] .
MicroRNAs and epigenetic regulation
MicroRNAs (miRNAs) regulate functions of both normal stem cells and CSCs [55] [56] [57] [58] , and dysregulation of miRNA expression has been implicated in tumorigenesis [59] . Yu et al. provided the first evidence for the significant downregulation of let-7 in CSCs [60] . A wide range of cancer types are characterized by overexpression of Lin 28, a factor that binds to miRNAs including let-7. Blockage of let-7 miRNA biogenesis and subsequent derepression of let-7 miRNA target genes by Lin28 plays important roles in cancer progression and metastasis. Lin28 is activated in CSCs (for review see [61] ). The Struhl laboratory has provided evidence for the role of miR-200 family members in regulating CSC plasticity in breast cancer patients [62, 63] . Overexpression of miR200b and miR-200c strongly inhibits the proliferation and tumorigenicity of breast cancer cells. This affect is mediated by regulation of polycomb repressor complex (PRC) proteins [57, 62] . This complex influences chromatin structure and regulates transcriptional activity of a number of important loci including the Ink4a locus, which encodes the tumor suppressor proteins p16
INK4a and p19 ARF (also called p14 ARF when referring specifically to the human version). Proteins in PRC1 cooperate with PRC2 to serve as transcriptional repressors by binding to histones displaying histone H3 lysine (H3K27) trimethylation [64] .
The CSC population overexpresses enhancer of zeste homolog 2 (EZH2), one of the key members of PRC2, responsible for trimethylating H3K27 in various cancers including breast, pancreas, prostate, and ovary [65, 66] . EZH2 is essential for maintenance of an intact CSC population. Furthermore, BMI-1 (for B cell specific Moloney murine leukemia virus integration site 1) and EZH2 are overexpressed in CSCs and necessary for initiation of various solid tumors such as head and neck cancers and glioblastoma [67] . BMI-1 complexes with other PRC1 and PRC2 proteins to repress the expression of genes bearing H3K27 histone marks including those encoding INK4a/ ARF and HOX [68, 69] . BMI-1 expression is negatively regulated by miR-200c.
The Weinberg laboratory reported that microenvironmental signals, such as TGFb, enhance CSC plasticity. In response to signals, the promoter of ZEB1 (for zinc-finger E box-binding homeobox 1) converts from bivalent to active chromatin by reductions in the presence of H3K27me 3 repressive histone modifications. This in turn induces non-CSC to CSC conversion in breast cancer [70, 71] . miR-200 and ZEB1 have antagonizing effects, and inhibition of miR-200 increases ZEB1 mRNA levels and the CD44 low -to-CD44 hi transition in HME-flopc cells. This is abrogated when ZEB1 levels are reduced, which indicates that ZEB1 is a key miR-200 target. miR-200c represses the expression of BMI-1, and loss of miR-200b increases levels of suppressor of zeste 12 homolog (SUZ12) expression and H3K27 methylation [57] . Interestingly, ectopic expression of SUZ12 in transformed cells generates CSCs [63] . In addition, miR-200c levels are regulated by a complicated loop involving BMI-1 and ZEB1 [72] .
These findings revealed that miR-200 family members are essential in regulation of CSC formation and function via PRC1 and PRC2 complexes. miR-200 is also involved in modulating the expression of SRY (sex determining region Y)-box 2 (SOX2), Kruppel-like factor 4 (KLF4), BMI-1, and SUZ12 genes, to regulate stemness in cancer cells [57, 73] . The Tang laboratory found that miR-34a is a key negative regulator of CD44
C prostate cancer cells. In addition, miR-34a directly targets stem cell-related genes like CD44 and NOTCH, implying that these miRNAs maintain the CSC phenotype by halting their differentiation [74] .
Metastatic capacity of CSCs
There is much discussion regarding the metastasis of cancer stem cells. Some studies have indicated that subpopulations of tumorigenic pancreatic cancer [75] and colon cancer [76] cells are enriched for the capacity to metastasize. The Wicha laboratory found that breast cancer cell lines contain functional CSCs with metastatic capacity and a distinct molecular signature [77] . Using a molecular tracking approach, Dieter et al. identified a population of extensively self-renewing, long-term tumorinitiating cells (LT-TICs) [78] . The vast majority of LT-TIC clones are able to form metastases, suggesting that this subpopulation may be responsible not only for tumor regeneration, but also for tumor dissemination. We have recently shown that a subpopulation of CD44 C CSCs that express cellular prion protein promote EMT via ERK2, thereby contributing to metastatic capacity of colorectal cancer [15] . 
Role of IL-6 and RTK signaling in CSC
Introduction of an activating mutant of STAT3 is sufficient to induce transformation of immortalized cells [81] , suggesting that activation of the JAK-STAT signaling pathway is sufficient to mediate tumorigenesis. More recent studies have suggested that STAT3 activation is important for the tumorigenic ability of CSCs in glioblastoma [82, 83] , lung [84] , and colon cancers [85, 86] . Moreover, IL-6 plays a crucial role in maintaining CSC plasticity [80] . As downstream targets, IL-6 regulates CSC-associated OCT4, SOX2, NANOG, and CD44 gene expression ( Figure  2 ), which converts non-CSCs into CSCs [43] .
Recent proteomic data indicate an alliance of PI3K and STAT3 in cancers. In glioblastoma stem cells, STAT3 is phosphorylated on residue Y705 and activated in a PI3K-dependent manner. A dominant negative mutant of STAT3 interferes with PI3K-induced oncogenic transformation. Phosphorylation of STAT3 is mediated by the Tec family kinase BMX [87] . The RTK pathways are mediated by the proto-oncogene members of the EGFR/ErbB(Her2) family, which are highly expressed and deregulated in many cancers including glioblastomas and breast and head and neck squamous cell carcinomas [88] [89] [90] . Activation of EGFR promotes the acquisition and maintenance of various CSC characteristics including the expression of selfrenewal markers (CD44, BMI-1, Oct-4, NANOG, CXCR4, and SDF-1) and capacity to form tumorspheres. Accordingly, EGFR/Her2 targeting with Gefitinib, erlotinib, lapitinib, or anti-ErbB2 monoclonal antibody trastuzumab results in the decrease in cancer initiating cells and the decrease in their resistance to chemotherapy drugs [91] . The EGF-RTK signaling pathway acts as a link between Hedgehog and IL-6 signaling [92] . PI3K activated via EGFR signaling can turn on Gli activator (Gli A) via the PI3K-AKT-mTORC1-S6K pathway to induce the expression of CSC-specific genes or expression of ligands, such as Jagged 2, that activate classical stem cell signaling pathways.
Hypoxia (or low oxygen (O 2 ) levels) is believed to be involved in tumor progression and metastasis. Hypoxia provides tumor cells with cues for maintenance of a stemlike state and may help to drive the linkage between EMT and CSCs. Hypoxia has been shown to dramatically increase the CD133 C stem cell fraction in a variety of cancers and consequently drives the CSC phenotype. Hypoxia-inducible factors (HIFs), particularly HIF1a and HIF2a, are key mediators of the cancer hypoxia response and high expression levels of HIFs correlate with a poor prognosis in various tumor types [93] . HIF2a acts as a transcriptional activator of stemness-specific genes OCT4, SOX2, CD44, KLF-4, and MYC, among other [51] . Unlike of HIF2a, HIF1a is activated via PI3K-AKT to induce expression of Twist1, an EMT modulator, and polycomb repressor BMI-1 to support the downregulation of p16 and p19 that are required for the differentiation of CSCs. It is noteworthy that these newly discovered signaling pathways act in synergistic manners with the overall result of inducing stemness. Further elucidation of the complex crosstalk among these pathways will increase our understanding of CSC plasticity.
AUTOPHAGY IN CANCER CELLS
5.1 Tumor-suppressing and tumor-promoting functions of autophagy The modulation of autophagy is now recognized as one of the hallmarks of cancer cells. There is accumulating evidence that autophagy plays a role in each of the various stages of tumorigenesis. Depending on the type of cancer and the context, autophagy fulfils a dual role, having both tumor-promoting and tumor-suppressing properties. Recent studies have shed light on the role of autophagy in the immune response to tumor growth. Readers interested in a more detailed discussion of the role of tumor suppressors and oncogenes in the regulation of autophagy should see several recent reviews [94, 95] . The first link between autophagy and tumor suppression came from the discovery that monoallelic disruption of BECN1 on chromosome 17q21 is observed in 40% to 75% of human breast, ovarian, and prostate tumors [96, 97] . In addition, the heterozygous deletion of BECN1 in mice increases spontaneous malignancies [98] , whereas restoration of its expression in breast cancer cells inhibits tumor growth in a mouse xenograft model [96] . However, recently data suggests that, contrary to these previous reports, BECN1 is not significantly mutated in human cancer and therefore is not a classic tumor-suppressor gene [99] .
Autophagy is stimulated by tumor suppressors (PTEN, TSC1/TSC2, LBK1, DAPK, p19 Wnt signaling begins when one of the Wnt proteins binds to a Frizzled (Fz) family receptor. Co-receptors, such as lipoprotein receptor-related protein (LRP)-5/6, receptor tyrosine kinase (Ryk), and ROR2, may facilitate Wnt signaling. Upon activation of the receptor, Fz and LRP recruit the Disheveled protein (Dvl) to the intracellular side of the cell. Dvl then recruits glycogen synthetase kinase 3 (GSK3) to phosphorylate LRP and inhibit phosphorylation of beta-catenin. The inhibition of the phosphorylation of beta-catenin releases it from conjugation to ubiquitin. Thus, the beta-catenin is released from the "degradation complex" and translocates into the nucleus increase the activity of target genes. Several kinases including GSK3 connect the Wnt and Hh pathways.
In the absence of Hh, the transmembrane protein Patched (PITCH1) inhibits signaling from the Smoothened molecule (Smo). In this state, full-length Gli is phosphorylated then cleaved to its repressor form (GliR) and enters the nucleus where it represses transcription of target genes. Upon Hh binding to PITCH1, the complex is internalized, allowing Smo activation. Cleavage of Gli is inhibited and the full-length activator form (GliA) enters the nucleus and activates transcription of target genes. A complex of molecules regulates the cytoplasmic/nuclear translocation of Gli.
BMI-1 acts as a major regulator of CSC self-renewal and plasticity. BMI-1 expression is negatively regulated by miRNAs such as mir-200c. BMI-1 forms an essential component of polycomb regulatory complex 1 (PRC1). PRC1 has a fundamental role in the organization of chromatin structure, which, in turn, regulates the expression of a cassette of genes involved in stem-cell behavior. These genes include the INK4A/ARF and HOX. Proteins in the PRC1 complex cooperate with PRC2 complex proteins to serve as transcriptional repressors by binding to histones displaying histone H3 lysine (H3K27) trimethylation. BMI-1 may also cooperate with TWIST1 to regulate the EMT, a state associated with CSCs and metastasis.
oncogenes (AKT/PI3K, BCL-2, RAS, c-MYC, tyrosine kinase receptors). The proto-oncogene c-Myc has been shown to induce autophagy independently of its oncogenic property. Factors encoded by these tumor suppressors have inhibitory effects on mTORC1 activity and those encoded by the oncogenes inhibit ULK1 initiation complex or Beclin-1 (for review see [95] ). In ensuring cellular homeostasis in healthy cells, autophagy prevents excessive ROS production and the resulting DNA damage and genomic instability, which can lead to tumoral transformation. Indeed, it has been shown that tumors formed by autophagy-deficient cells (by biallelic loss of Atg5 or monoallelic loss of Beclin1 [96] ) display genomic instability and unrepaired DNA damage, resulting from ROS generation and impairment of autophagy-mediated removal of damaged organelles, especially mitochondria [100] [101] [102] . Clinical observations show that, low or deficient Beclin-1 expression is associated with shorter overall survival in some cancers, whereas elevated Beclin-1 levels appear to be associated with a more favorable prognosis [103] . Interestingly, it has been recently demonstrated that STAT3 inhibits Beclin-1 expression by directly binding to the BECN1 promoter and recruitment of histone deacetylase 3 (HDAC3) in non-small cell lung cancer cells [104] . An inverse correlation between phosphorylated STAT3 and Beclin-1 was reported in glioma samples [105] . In addition, mutations of other ATG genes, such as ATG2B, ATG5, ATG9B, and ATG12, are found in gastric and colorectal cancers. Mice deficient in Atg4C, a cysteine protease required for the processing of LC3, have increased susceptibility to chemically induced fibrosarcomas [106] , and mice deficient for Atg5 or Atg7 develop benign liver tumors [107] . Overall, the data suggest that a defective autophagic process is clearly linked to cancer development. A systematic review and meta-analysis of the prognostic value of BECN1 and LC3B indicated that the BECN1 appears to be predictive of favorable prognosis in gastric cancer, breast cancer, and lymphoma and that LC3B may predict unfavorable prognosis of breast cancer. Due to the limited number of patients and retrospective design of the original studies, more powerful prospective cohorts are required to verify these conclusions [108] .
The most commonly mutated tumor suppressor gene is p53. p53 plays opposing roles in the regulation of . The master negative regulator of autophagy initiation is the mammalian target of rapamycin complex 1 (mTORC1), which integrates multiple signaling pathways. Activation of the EGFR-class I PI3K-AKT-mTOR signaling axis inhibits autophagy. EGFR signaling acts as a link between Hedgehog and IL-6 signaling. STAT3 is a master regulator of IL-6 signaling. Recently, an alliance of PI3K and STAT3 mediated by the TEC kinase BMX was discovered. STAT3 is phosphorylated on residue Y705 and activated in a PI3K-dependent manner. New data identify STAT3 as an autophagy regulator. In the cytoplasm, STAT3 interacts with the PKR kinase to inhibit eIF2A phosphorylation and reduce autophagy. STAT3 activation disrupts the interaction with PKR kinase resulting in eIF2A activation and subsequently induction of autophagy. This non-canonical function of STAT3 has an important role in normal cells, and we suggest that it might also affect CSCs.
autophagy that depend on its subcellular location. It acts as a pro-autophagic nuclear factor and an anti-autophagic cytoplasmic factor, reflecting the spatial control of p53 signaling (for review [109] ). Autophagy may also prevent cancer by regulating the cellular level of p62 (also known as SQSTM1) [110] . Accumulation of p62 in autophagydeficient cells promotes tumorigenesis. p62 serves as a cytoplasmic scaffold protein and activates pro-survival and pro-inflammatory transcription factors NF-kB and NRF2; these factors upregulate expression of antioxidant genes to protect cells during oxidative stress [111, 112] . Interestingly, p62 mediates activation of mTORC1 by interacting with Raptor. Once a tumor is established, autophagy can contribute to tumor progression, by allowing tumor cells to survive stressful conditions (e.g., hypoxia, acidosis, nutrient deprivation) and by sustaining the deep metabolic reorganization that cancer cells undergo after oncogenic transformation. The first genetic clue that autophagy is necessary for the progression and survival of tumors came from the observation that the deletion of BECN1 is only observed on one allele in human cancers; this suggests that tumor cells require functional autophagy for malignant transformation [113] . In addition, deletion of the essential autophagy gene FIP200 impairs oncogene-induced tumorigenesis in a mouse model of breast cancer [114] . In solid tumors, autophagy localizes to the hypoxic regions or the poorly vascularized regions, and its inhibition induces the cell death specifically in these regions [102] . This induction of autophagy in hypoxic regions is regulated independently by HIF-1a and the AMPK signaling pathway. Stabilized HIF-1a induces the BH3-only protein BNIP3, which disrupts the interaction between Beclin-1 and Bcl-2 or Bcl-xL, allowing Beclin-1 to induce autophagy [115] . In contrast, AMPK mediates mTOR kinase inhibition, thus turning on autophagy [116] . A mouse model of RASmediated non-small cell lung cancer, in which the tumorsuppressive and tumor-promoting function of autophagy can be visualized, it has been demonstrated that autophagy also promotes tumor growth by suppressing the p53 response, maintaining mitochondrial function, and sustaining metabolic homeostasis and survival in stress. In a mouse model of RAS-mediated lung tumor autophagy prevents diversion of tumor progression to benign oncocytomas [117] . In mammary cancers, partial autophagy impairment due to allelic loss of Becn1 increases apoptosis and significantly delays mammary tumor development following PALB2 or BRCA1/BRCA2 loss but only when p53 is present [118] . Thus, autophagy may promote mammary tumor growth by suppressing p53 activation induced by DNA damage.
Autophagy and tumor cell metabolism
The "Warburg effect" is a hallmark of tumors: Cancer cells upregulate aerobic glycolysis and reduce the activity of mitochondrial electron chain transport thus increasing the rate of energy production (despite reducing its efficiency). Thus, the enhanced conversion of glucose to lactate is observed in tumor cells, even in the presence of normal levels of oxygen. Aerobic glycolysis supports various biosynthetic pathways and, consequently, the metabolic requirements for proliferation. The PI3K pathway is considered to be a master regulator of the glycolytic phenotype through AKT1 and mTOR signaling and subsequent downstream HIF-1 activation. The AMP-activated protein kinase (AMPK) pathway is also important. AMPK is considered a metabolic checkpoint as it can control cell proliferation when activated under energetic stress, and activation of AMKP results in the inhibition of mTOR activity and subsequent autophagy induction.
Oncogenic transformation (e.g., due to RAS, C-MYC, AKT) is characterized by a deep metabolic reprogramming resulting in upregulation of aerobic glycolysis in favor of the activity of oxidative phosphorylation [119] . Thus, using preferentially glucose, the metabolic demand of cancer cells is higher than that of normal cells, and autophagy may help overcome cellular energy deficits [120] . Indeed, human cancer cell lines bearing activating mutations in RAS commonly have high levels of basal autophagy. In a subset of these cancer cells, downregulation of essential autophagy proteins (for example, by knockout of ATG5 or by treatment of cells with an shRNA targeting ATG7) abolishes their tumorigenicity and reduces glucose metabolism indicating the high dependence of autophagy for their survival [102, [121] [122] [123] . Autophagy may contribute to metabolism rearrangement by targeting the degradation of damaged mitochondria resulting in the decrease of oxidative phosphorylation. Both RAS and c-MYC impair acetyl-CoA production (by blocking its generation from the decarboxylation of pyruvate and the b-oxidation of fatty acids [122] ) cancer cells have to maintain oxidative metabolism for their survival [123] . Thus, autophagy might maintain functional mitochondria by providing substrates to replenish the mitochondrial TCA cycle by amino acids (such as glutamine resulting in high-energy metabolites), through protein or lipid degradation, or through the degradation of membrane organelles or lipid droplets and sugars [122] .
Autophagy and tumor cell dissemination and
metastasis Autophagy may also promote tumor cell dissemination and metastasis by protecting these cells from anoikis, which is a form of programmed cell death induced by the detachment of anchorage-dependent cells from the extracellular matrix. Indeed, it has been demonstrated that this detachment from the extracellular matrix is a critical step in dissemination. In addition, metastasis induces prosurvival autophagy in epithelial cells to protect them from anoikis, and depletion of ATG protein enhances cell death and reduces clonogenic recovery after anoikis [124, 125] .
AUTOPHAGY IN STEM CELLS
Both embryonic and adult stem cells are unique cell populations characterized by their ability to self-renew and differentiate into various cells in the body. Embryonic stem cells ensure appropriate development, whereas adult stem cells enable tissue renewal and cellular homeostasis. Therefore, it was expected that autophagy would play a crucial role in the quality control mechanisms and maintenance of cellular homeostasis in various stem cells given their relatively long life in organisms. Accumulating evidence has provided insights into the crucial role of autophagy in embryonic stem cells (ESCs), and tissue stem cells that persist throughout the adult life including hematopoietic stem cells (HSCs), cardiac or neural stem cells, and mesenchymal stem cells (MSCs). Autophagy regulates self-renewal, pluripotency, differentiation, and quiescence (for review see [126] [127] [128] ). Recent advances in metabolomic analysis and studies in mouse models indicate that metabolic reprogramming (i.e., stem cell-specific programs that may drive the dependency of stem cells on specific nutrients, such as glucose, fatty acids and glutamine, as well as impose changes to the wiring of metabolic pathways to maintain stemness) is also required for the maintenance of stem cell self-renewal [129] . Various types of stem cells heavily rely on anaerobic glycolysis. Maintenance of the stem cell pool and of self-renewing stem cells are regulated by bioenergetic signaling that involves the AKT-mTOR pathway, fatty acid metabolism, and glutamine metabolism.
AUTOPHAGY IN CANCER STEM CELLS

Cancer stem cell-associated microenvironment
and autophagy Sharing the same properties as 'natural' stem cells, accumulating evidence also support the essential role of autophagy in the maintenance and the self-renewal of cancer stem cells (CSCs) in several histological types of cancer including breast, glioblastoma, and pancreatic cancers [130] [131] [132] [133] . Firstly, autophagy has been predicted to ensure a cytoprotective adaptive mechanism to overcome tumor microenvironmental stress in solid epithelial tumors. The molecular tumor microenvironment is characterized by hypoxia or oxygen-limiting areas, oxidative stress, depletion of nutrients or growth factors, and high levels of metabolic derivatives including L-lactate, resulting in extracellular acidosis [42, 134] . 7.1.1 Extracellular microenvironment CSCs are frequently located at the hypoxic core of solid tumors including breast, pancreatic, and colorectal cancers as well as glioblastoma multiforme (a vascularized tumor) [135, 136] . In addition, hypoxia appears to play a critical role in the formation of the CSC niches [137] . For example, anti-angiogenic treatments of patients with breast cancer or glioblastoma results in hypoxia-mediated autophagy that promotes tumor cell survival and results in an increase in the population of CSCs [138, 139] . In the case of the pre-malignant lesions, breast ductal carcinoma in situ (DCIS), the capacity of CSC-like precursor cells to survive in the hypoxic and nutrient-deprived environment of the intraductal niche is dependent on the activation of autophagy (which is associated with up-regulation of BECLIN-1, ATG5, MAP1LC3A/B) [140, 141] . As described above, the effects of hypoxia are mainly mediated by the transcriptional regulators HIF-1a and HIF-2a. Multiple recent experimental studies have revealed that these two factors are required for maintaining the phenotype and function of CSCs in glioblastoma, neuroblastoma, renal cancer, and non-small cell lung cancer (for review see [142] ). They stimulate autophagy by inducing expression of autophagy-regulating genes including BNIP/BNIP3L (belonging to BH3-only family). By disrupting the interaction between Beclin-1 and Bcl-2, these factors allow Beclin-1 to induce autophagy and to promote survival [115] ). In addition, hypoxia-induced BNIP targets mitophagy resulting in the clearance of damaged mitochondria and reducing ROS production [143] . High levels of intracellular ROS promote both the loss of selfrenewal and differentiation and the radiosensitization of tumor-initiating cells for several types of cancer, including breast, glioma, and prostate [144] [145] [146] , indicating that redox status plays an important role in stem cell maintenance (for review see [147, 148] ). The autophagic degradation of mitochondria leads to low levels and activities of mitochondria and promotes glycolysis, which characterizes both stem cells and CSCs (the Warburg effect or Warburg-like glycolytic metabolism) in aid of mitochondria-driven oxidative phosphorylation [149] .
Although not focused specifically on CSCs, studies have demonstrated that deletion of FIP200 or other autophagy genes in oncogene-driven mammary tumor mouse models of human breast cancer significantly suppresses mammary tumorigenesis and progression [114, 150] . Proliferation of tumor cells was reduced in vitro and in vivo, and there was a significant decrease in anchorage-independent growth in soft agar. This was correlated with a compromised glycolysis resulting in an impaired glucose uptake and intracellular lactate production. Collectively, these studies highlight the active contribution of autophagy to malignant transformation and in the acquisition or the maintenance of stemness by CSC-like cell populations through support for the metabolic shift.
Cellular microenvironment
Although not formally determined, it is likely that autophagy play a crucial role in the microenvironment of CSCs. We know this indirectly for certain parameters such as the autophagy-mediated unconventional secretion and expression of pro-inflammatory cytokines [151, 152] , as these cytokines are able to modulate the autophagic response by the activation of the IKK/NF-kB signaling [153] and the JAK/STAT3 pathway [154] . In addition, several groups of researchers have demonstrated that autophagic CAFs exposed to oxidative stress (H 2 O 2 , ROS) produce energy-rich glutamine, L-lactate, and ketones to "fuel" the mitochondrial activity of cancer cells by their conversion into acetyl-CoA, which is associated with the CSC phenotype [152] . Indeed, the use of L-lactate and ketones by cancer cells promotes a "stemness-like" transcriptional profile that is specifically associated with tumor recurrence, metastasis, and poor clinical outcome. This seems to be mediated by acetyl-CoA, which promotes mitochondrial-dependent ATP production and acetylation of proteins (including histones), both implicated in the epigenetic control of gene expression. Interestingly, evidence is accumulating that acetylation and posttranscriptional modifications, including phosphorylation, ubiquitination, and lipidation, are involved in the complex regulatory network that controls autophagy, and these modifications likely constitute the connection between autophagy and cellular metabolism (see for review [155] ). However, it remains to be determined how autophagy contributes to the metabolic shift of cancer cells and the acquisition of 'stemness' by CSC-like cell populations, although all are linked to acetyl-CoA status.
Autophagy, a hallmark of cancer stem cells
We recently showed that autophagy is also crucial for the maintenance and tumorigenicity of CSCs in breast cancer [130, 156] . From breast tumor cells isolated from patients and from human breast cancer cell lines, mammospheres that are enriched in breast CSCs display a significantly higher level of autophagy flux than the adherent counterparts, both at basal levels and under starvation conditions. Furthermore, cells positive for aldehyde dehydrogenase 1 (ALDH1, a cancer stem cell marker, see Table 1 ) derived from mammospheres constitutively present higher levels of autophagy flux than do the bulk tumor cell populations both at basal levels and under starvation conditions. This robust autophagic flux is associated with up-regulation of Beclin-1 at the protein and mRNA levels in breast CSCs/ progenitor cells. The specific depletion of BECN1 or ATG7 or treatment with salinomycin (a chemical inhibitor of autophagic flux [157] ) dramatically reduces both the size and formation efficiency of mammospheres, reflecting the alteration of the proliferation and the self-renewal ability, respectively, of CSCs/progenitor cells. More importantly, the suppression of autophagy in breast CSCs/progenitor cells by Beclin-1 depletion inhibits their tumorigenicity in nude mice. Our data are consistent with those reported by Wei et al., indicating that the suppression of autophagy by the deletion of FIP200, an important regulator of autophagy in mammalian cells, inhibits mammary tumorigenesis [114] . Moreover, different autophagy-associated factors such as DRAM1 and p62 (also known as sequestosome 1 (SQSTM1) are highly expressed in glioblastomas that exhibit a mesenchymal gene signature and aggressive phenotypes associated with a poor overall survival [132] . The enhanced expression of DRAM1 and p62 also correlate with up-regulated expression of the mesenchymal marker MET, activation of MAPKs, and enhanced motility and invasion of glioma stem cells [132] . Since impairment of the autophagic response dramatically decreases the CD44 C CD24 À/Low breast CSC-like cell population [131] , crosstalk likely exists between autophagy and stemness-associated pathways that support survival and CSC-like properties. Critical pathways include classical stem cell signaling pathways involving Wnt/b-catenin, Notch, and Hedgehog (Hh) and the novel RTK and IL-6/JAK/STAT3 pathways.
Hedgehog pathways
To date, a relationship between Hh and autophagy pathways has been reported in the neuroblastoma cell line SHSY5Y [158] , pancreatic ductal adenocarcinoma cells [159] , the cervical HeLa cell line [160] , a chondrosarcoma cell line [161] , and a hepatocarcinoma cell line [162] . Under starvation conditions, the inhibition of the Hh pathway by the Hh antagonist cyclopamine reduces autophagic flux in tumor cells and is associated with a decrease in Atg5 expression, suggesting transcriptionally mediated regulation of key autophagic genes by Hh signaling. This same study also reported the presence of the multiple nonconsensus GLI binding sites in the human ATG5 promoter [158] . More recently, however, it was shown that Hh signaling negatively regulates autophagy in pancreatic cancer cells [159] . In support of this, treatment of cultured human hepatocarcinoma cells with an Hh signaling ligand (recombinant Sonic Hh) or either of the agonists SAG or purmorphamine prevents the induction of autophagy; in contrast, GANT61 (a small molecule inhibitor of Gli1 and Gli2) induces autophagy [162] . Hh inhibition-induced autophagy is associated with up-regulation of Bnip3, leading to Bnip3-mediated displacement of Bcl-2 from Beclin-1 and induction of apoptosis. More importantly, in a tumor xenograft mouse model, administration of GANT61 inhibits tumor formation in vivo and decreases tumor volume; this effect is partially blocked by the autophagy inhibitor 3-MA [162] . It is crucial that the connection between the Hh pathway and autophagy, in particular in cancer stem cells, must to be clarified. Of note, Hh has recently been proposed to be a general positive metabolic regulator in cancer [163] and might act in concert with autophagy to influence the survival and the maintenance of CSCs.
Notch pathways
The Notch signaling pathway (Figure 2 ) is critical in CSCs from different cancers including breast, pancreas, melanoma, lung, and glioblastoma [164] [165] [166] [167] [168] . Aberrant activation of Notch signaling, characterized by high levels of Notch-1, Notch-2, and Jagged-1 ligand, is associated with CSC features [169, 170] . Accordingly, the inhibition of Notch signaling depletes the CSC population and reduces their sphere-forming ability, which reflects stem cell self-renewal ability, and their tumorigenicity in immunodeficient mice [166] . Moreover, it was reported that the activation of Notch signaling pathways is mechanistically linked with the acquisition of the EMT phenotype and the generation of CSCs in pancreatic cancer [171] . In addition, known specific chemical inhibitors of the Notch pathway, sulforaphane, quercetin, curcumin, and isoflavone are also able to inhibit activation of the Notch pathway cancers of the pancreas and breast models [172] . However, the molecular mechanism through which Notch signaling regulates CSC features remains undefined and its action on autophagy in CSCs has not yet been explored. Notch target genes Akt, mTOR, ERK, NF-kB, p53, and VEGF, are known to modulate or regulate autophagy [173, 174] , may also have effects on the CSC phenotype.
Wnt pathways
The Wnt/b-catenin signaling pathway also plays a crucial role in the acquisition of the CSC phenotype [175, 176] . The inhibition of the Wnt/b-catenin signaling pathway results in a decrease in sphere-forming ability of tumor cells derived from breast cancer and melanoma, reflecting the self-renewal of CSCs, reduces tumorigenic capacity (or tumor-initiating potential) of these cells in mice, and enhances their sensitivity to drug-mediated apoptosis [177, 178] . Wnt/b-catenin signaling regulates OCT4 at transcriptional level the expression. OCT4, in concert with other transcription factors such as Nanog and Sox2, controls the self-renewal and the maintenance of CSCs [179] . The Wnt/b-catenin signaling pathway is also involved in the induction of EMT, which is closely related to the acquisition of a stemness phenotype [180] [181] [182] . b-catenin is also known to facilitate adaptation to microenvironmental conditions including hypoxia [183] and oxidative stress [184] , and it has been clearly demonstrated that Wnt/ b-catenin signaling negatively regulates both basal and stress-induced autophagy and p62 expression via T cellspecific transcription factor 4 (TCF4) both in vitro and in vivo [185] . Furthermore, during nutrient deprivation, b-catenin is selectively degraded via the formation of a b-catenin-LC3 complex, attenuating b-catenin/TCFdriven transcription and proliferation to favor adaptation during metabolic stress. Thus, these findings reveal a regulatory feedback mechanism that places b-catenin at a key cellular integration point coordinating proliferation with autophagy.
Autophagy has also been shown to negatively regulate Wnt signaling by promoting Disheveled (Dvl) degradation in starvation condition [186] . The degradation of Dvl is mediated by its ubiquitylation, which promotes p62 association and subsequently its p62-mediated binding of LC3. Dvl also interacts directly with LC3 through its LC3-interacting region (LIR) [187] . There is an inverse correlation between Dvl expression and autophagy markers in late stages of human colon cancer, indicating that the impairment of autophagy may contribute to aberrant Wnt activation during cancer development [186] . Thus, these findings, which might be extended to CSCs, support a regulatory feedback model between Wnt signaling and autophagy that functions to integrate information from different signaling pathways.
Receptor tyrosine kinase pathways
During autophagy, EGFR activates the ras and raf-1 mitogen-activated protein kinase pathways and the PI3K/AKT pathway. These pathways activate mTOR signaling resulting in the inhibition of autophagy [95] . It was recently demonstrated that elevation of autophagy in gefitinib-treated breast cancer cells is correlated with downregulation of AKT and ERK1/2 signaling early in the course of treatment [188] . More importantly, active EGFR is able to interact with Beclin-1 leading to its multisite tyrosine phosphorylation, enhanced binding to inhibitors, decreased Beclin-1-associated VPS34 kinase activity, and subsequently suppression of autophagy (Wei, Y. et al., 2013 cell). Interestingly, this same study showed that in non-small-cell lung carcinoma tumor xenografts, the expression of a tyrosine phosphomimetic Beclin-1 mutant leads to reduced autophagy, enhanced tumor growth, tumor dedifferentiation, and resistance to EGFR tyrosine kinase inhibitor therapy. Thus, oncogenic receptor tyrosine kinases are able to directly regulate the core autophagy machinery, which may contribute to tumor progression and chemoresistance. As illustrated in Figure 2 , the EGFR signaling pathway acts as a link between Hh and IL-6 signaling via mTOR signaling and nonreceptor tyrosine kinase BMX/STAT3 signaling, respectively [23] .
IL-6/JAK/STAT3 pathways
It has been clearly demonstrated in breast cancer that the IL-6/JAK/STAT3 pathway is important for CSC plasticity as it promotes the selection and expansion of CD44 high / CD24 low cells [189, 190] . Like IL-6, OSM (which belongs to the same family of pro-inflammatory cytokines) is a robust stimulator of STAT3 and promotes emergence of CSCs, and EMT programs [44, 191] . Recent data have identified STAT3 as a cytoplasmic autophagy regulator. STAT3 interacts with the PKR kinase in the cytoplasm resulting in the inhibition of eIF2A phosphorylation and in the reduction of the activity of the autophagic pathway ( Figure 3 ). Upon activation, STAT3 dissociates from PKR resulting in activation of eIF2A and subsequent induction of autophagy [154, 192] . Additionally, genetic or pharmacological inactivation of STAT3 reduces LC3-II levels in pancreatic cancer cells, again indicative of a role for STAT3 in transcriptional regulation of autophagy [193] . Since STAT3 is activated by both inflammatory and oxidative stress signaling, STAT3 might play a vital role in the regulation of autophagy through its contributions to the positive feedback loop between ROS and autophagy, [226, 227] (Continued on the following page)
which is crucial in CSCs. In addition, the phosphorylation and activation of STAT3 mediated by mTORC1 have been reported [194] . Activation of the mTORC1-STAT3 pathway, which is connected with autophagy signaling, is required for the viability and the maintenance of breast cancer stem-like cells [195] . It remains to be determined, however, how autophagy mediated by this pathway contributes to the maintenance and the plasticity of CSCs.
THERAPEUTIC MODULATION OF AUTOPHAGY IN CSC AND CONCLUDING REMARKS
In addition to its evolutionarily conserved role in promoting cell survival during metabolic stress, autophagy also plays an essential role in determining how cancer cells respond to therapy and changing environmental stimuli [95, 196] . Drug resistance that results in tumor relapse remains a major obstacle to improvement of cancer patient survival, and drug resistance may be due at least in part to the existence of CSCs. Table 2 summarizes the numerous studies that have investigated compounds that likely target CSCs through pathways involved in autophagy regulation; these compounds include inhibitors of mTOR, Akt, the proteasome, tyrosine kinases, HDAC, IL6 signaling, hypoxia, farnesyl transferase, Notch, Hh signaling, and Wnt signaling. Only a few studies, including ours [157] , have reported positive effects of therapeutic agents on modulation of autophagy in CSCs (Table 2 , modulation of ATG column). Depending on the type of cancer and the compound, inhibition or induction of autophagy has been observed. For example, in one study, it was shown that the autophagy inhibitor chloroquine targets pancreatic CSCs via inhibition of CXCR4 and hedgehog signaling independently of autophagy [197] .
For complete eradication of cancer, it may be necessary to target both CSCs and non-CSC populations. The crosstalk between tumor microenvironment and CSCs is believed to be the key source for cancer cell differentiation and bidirectional conversion [70] . The factors responsible for bidirectional conversion of cancer cells have yet to be identified, and the relationship between this conversion and autophagy is not understood. Taking into account of the concept CSC plasticity, cancer therapy should both target CSCs and also prevent CSC generation from nonCSCs (Figure 1 ). It also remains to be determined whether CSCs display 'oncogene addiction'. This phenomenon is characterized by an absolute dependence of tumor cells on continued oncogene expression for their survival, and it has been proposed that other tumorigenic cell populations show this dependence.
A few drugs, such as salinomycin [198] and metformin [199] , have been identified that target CSCs in vitro and in OMP-111118R5 Fzd ND [237] vivo. These compounds successfully eliminate CSCs and have been used alone or in combination with conventional chemotherapeutic drugs (for review see [200] ). Recently, a pharmacological inhibitor of BMI-1, PTC-209, was shown to effectively inhibit CSC self-renewal in vitro and to effectively block tumor growth in mouse xenografts [201] . Tumors failed to grow back following withdrawal of treatment, indicating that PTC-209 has irreversible effects. Furthermore unlike of salinomycin, PTC-209 inhibits tumor growth in the absence of apparent systemic toxicity. Further investigations of the molecular mechanism of CSC plasticity, the mode of action of CSC specific drugs, and the role of autophagy are required before highly effective therapies can be identified for patients in all stages of cancer. Previous preclinical studies have suggested that CSC-targeting agents will have the greatest efficacy when they are administered early or in an adjuvant setting alongside a primary therapy [69] . It will therefore be interesting to explore the efficacy of PTC-209 in such settings.
